DOSE-EFFECT RELATION OF CHOLESTYRAMINE IN CHILDREN AND YOUNG ADULTS WITH FAMILIAL HYPERCHOLESTEROLÆMIA

J. Ramsay Farah, PeterO Kwiterovich, CatherineA Neill

Research output: Contribution to journalArticle

Abstract

Twenty children and young adults with familial hypercholesterolæmia (F.H.), on a diet low in cholesterol and high in polyunsaturated fats, were treated with cholestyramine in a metabolic unit to determine the decrease in plasma cholesterol and low-density lipoprotein (L.D.L.) cholesterol in relation to drug dosage, pretreatment concentrations of cholesterol and L.D.L. cholesterol, and body-weight. When the dose of cholestyramine was increased in thirteen patients by 1 g/day up to 16 g/day, given twice daily, cholesterol and L.D.L. cholesterol fell within the normal range in eleven subjects (average dose, 7 g/day), and the response was directly proportional (P<

Original languageEnglish (US)
Pages (from-to)59-63
Number of pages5
JournalThe Lancet
Volume309
Issue number8002
DOIs
StatePublished - Jan 8 1977

Fingerprint

Cholestyramine Resin
Young Adult
Cholesterol
LDL Cholesterol
Reference Values
Fats
Body Weight
Diet
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

DOSE-EFFECT RELATION OF CHOLESTYRAMINE IN CHILDREN AND YOUNG ADULTS WITH FAMILIAL HYPERCHOLESTEROLÆMIA. / Ramsay Farah, J.; Kwiterovich, PeterO; Neill, CatherineA.

In: The Lancet, Vol. 309, No. 8002, 08.01.1977, p. 59-63.

Research output: Contribution to journalArticle

Ramsay Farah, J. ; Kwiterovich, PeterO ; Neill, CatherineA. / DOSE-EFFECT RELATION OF CHOLESTYRAMINE IN CHILDREN AND YOUNG ADULTS WITH FAMILIAL HYPERCHOLESTEROLÆMIA. In: The Lancet. 1977 ; Vol. 309, No. 8002. pp. 59-63.
@article{ee1198fe84524cd5a3bd6fcaf30635eb,
title = "DOSE-EFFECT RELATION OF CHOLESTYRAMINE IN CHILDREN AND YOUNG ADULTS WITH FAMILIAL HYPERCHOLESTEROL{\AE}MIA",
abstract = "Twenty children and young adults with familial hypercholesterol{\ae}mia (F.H.), on a diet low in cholesterol and high in polyunsaturated fats, were treated with cholestyramine in a metabolic unit to determine the decrease in plasma cholesterol and low-density lipoprotein (L.D.L.) cholesterol in relation to drug dosage, pretreatment concentrations of cholesterol and L.D.L. cholesterol, and body-weight. When the dose of cholestyramine was increased in thirteen patients by 1 g/day up to 16 g/day, given twice daily, cholesterol and L.D.L. cholesterol fell within the normal range in eleven subjects (average dose, 7 g/day), and the response was directly proportional (P<",
author = "{Ramsay Farah}, J. and PeterO Kwiterovich and CatherineA Neill",
year = "1977",
month = "1",
day = "8",
doi = "10.1016/S0140-6736(77)91078-9",
language = "English (US)",
volume = "309",
pages = "59--63",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8002",

}

TY - JOUR

T1 - DOSE-EFFECT RELATION OF CHOLESTYRAMINE IN CHILDREN AND YOUNG ADULTS WITH FAMILIAL HYPERCHOLESTEROLÆMIA

AU - Ramsay Farah, J.

AU - Kwiterovich, PeterO

AU - Neill, CatherineA

PY - 1977/1/8

Y1 - 1977/1/8

N2 - Twenty children and young adults with familial hypercholesterolæmia (F.H.), on a diet low in cholesterol and high in polyunsaturated fats, were treated with cholestyramine in a metabolic unit to determine the decrease in plasma cholesterol and low-density lipoprotein (L.D.L.) cholesterol in relation to drug dosage, pretreatment concentrations of cholesterol and L.D.L. cholesterol, and body-weight. When the dose of cholestyramine was increased in thirteen patients by 1 g/day up to 16 g/day, given twice daily, cholesterol and L.D.L. cholesterol fell within the normal range in eleven subjects (average dose, 7 g/day), and the response was directly proportional (P<

AB - Twenty children and young adults with familial hypercholesterolæmia (F.H.), on a diet low in cholesterol and high in polyunsaturated fats, were treated with cholestyramine in a metabolic unit to determine the decrease in plasma cholesterol and low-density lipoprotein (L.D.L.) cholesterol in relation to drug dosage, pretreatment concentrations of cholesterol and L.D.L. cholesterol, and body-weight. When the dose of cholestyramine was increased in thirteen patients by 1 g/day up to 16 g/day, given twice daily, cholesterol and L.D.L. cholesterol fell within the normal range in eleven subjects (average dose, 7 g/day), and the response was directly proportional (P<

UR - http://www.scopus.com/inward/record.url?scp=84919591017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919591017&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(77)91078-9

DO - 10.1016/S0140-6736(77)91078-9

M3 - Article

VL - 309

SP - 59

EP - 63

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8002

ER -